Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.
Please discuss the data for 2L treatment with CAR T-cell therapy for patients who are transplant-ineligible.
Do the defining characteristics of transplant-ineligible used in the following studies reflect which patients are considered transplant-ineligible in the real world?
ALYCANTE- Phase 2 trial.
PILOT – Phase 2 trial.
What are some key takeaways from the results of these two studies?